vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and SMARTFINANCIAL INC. (SMBK). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $53.8M, roughly 1.6× SMARTFINANCIAL INC.). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 15.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
SmartFinancial Inc. is a U.S.-based bank holding company that operates its wholly owned subsidiary SmartBank. It offers a full range of retail and commercial banking products including deposit accounts, personal and business loans, mortgage services, and wealth management solutions, primarily serving individual customers and small-to-medium enterprises across the Southeastern United States.
IOVA vs SMBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $53.8M |
| Net Profit | — | $13.7M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | — |
| Net Margin | — | 25.4% |
| Revenue YoY | 17.7% | — |
| Net Profit YoY | — | 21.6% |
| EPS (diluted) | — | $0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $53.8M | ||
| Q4 25 | $86.8M | $53.3M | ||
| Q3 25 | $67.5M | $51.1M | ||
| Q2 25 | $60.0M | $49.2M | ||
| Q1 25 | $49.3M | $46.8M | ||
| Q4 24 | $73.7M | $46.8M | ||
| Q3 24 | $58.6M | $44.2M | ||
| Q2 24 | $31.1M | $40.4M |
| Q1 26 | — | $13.7M | ||
| Q4 25 | — | $13.7M | ||
| Q3 25 | $-91.3M | $13.7M | ||
| Q2 25 | $-111.7M | $11.7M | ||
| Q1 25 | $-116.2M | $11.3M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | $-83.5M | $9.1M | ||
| Q2 24 | $-97.1M | $8.0M |
| Q1 26 | — | — | ||
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | -84.7% | 31.3% | ||
| Q3 25 | -140.7% | 33.2% | ||
| Q2 25 | -189.8% | 29.0% | ||
| Q1 25 | -245.8% | 29.0% | ||
| Q4 24 | -117.5% | 26.5% | ||
| Q3 24 | -152.1% | 24.3% | ||
| Q2 24 | -327.6% | 25.6% |
| Q1 26 | — | 25.4% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | -135.3% | 26.8% | ||
| Q2 25 | -186.2% | 23.8% | ||
| Q1 25 | -235.5% | 24.0% | ||
| Q4 24 | — | 20.6% | ||
| Q3 24 | -142.7% | 20.7% | ||
| Q2 24 | -312.2% | 19.8% |
| Q1 26 | — | $0.81 | ||
| Q4 25 | — | $0.81 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | $-0.33 | $0.69 | ||
| Q1 25 | $-0.36 | $0.67 | ||
| Q4 24 | $-0.24 | $0.57 | ||
| Q3 24 | $-0.28 | $0.54 | ||
| Q2 24 | $-0.34 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $346.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $562.2M |
| Total Assets | $913.2M | $5.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $346.1M | ||
| Q4 25 | $297.0M | $464.4M | ||
| Q3 25 | $300.8M | $557.1M | ||
| Q2 25 | $301.2M | $365.1M | ||
| Q1 25 | $359.7M | $423.0M | ||
| Q4 24 | $323.8M | $387.6M | ||
| Q3 24 | $397.5M | $192.9M | ||
| Q2 24 | $412.5M | $342.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | — | $7.0M | ||
| Q1 25 | — | $7.6M | ||
| Q4 24 | — | $8.1M | ||
| Q3 24 | — | $9.0M | ||
| Q2 24 | — | $12.7M |
| Q1 26 | — | $562.2M | ||
| Q4 25 | $698.6M | $552.4M | ||
| Q3 25 | $702.3M | $538.4M | ||
| Q2 25 | $698.5M | $519.0M | ||
| Q1 25 | $767.9M | $505.8M | ||
| Q4 24 | $710.4M | $491.3M | ||
| Q3 24 | $773.5M | $489.0M | ||
| Q2 24 | $768.5M | $472.5M |
| Q1 26 | — | $5.9B | ||
| Q4 25 | $913.2M | $5.9B | ||
| Q3 25 | $904.9M | $5.8B | ||
| Q2 25 | $907.4M | $5.5B | ||
| Q1 25 | $966.7M | $5.4B | ||
| Q4 24 | $910.4M | $5.3B | ||
| Q3 24 | $991.1M | $4.9B | ||
| Q2 24 | $964.3M | $4.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $61.7M | ||
| Q3 25 | $-78.7M | $16.9M | ||
| Q2 25 | $-67.4M | $14.0M | ||
| Q1 25 | $-103.7M | $14.3M | ||
| Q4 24 | $-73.3M | $52.7M | ||
| Q3 24 | $-59.0M | $12.4M | ||
| Q2 24 | $-98.4M | $16.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $59.3M | ||
| Q3 25 | $-89.5M | $16.6M | ||
| Q2 25 | $-74.9M | $13.2M | ||
| Q1 25 | $-109.9M | $13.4M | ||
| Q4 24 | $-77.5M | $46.3M | ||
| Q3 24 | $-61.3M | $11.3M | ||
| Q2 24 | $-98.9M | $15.4M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 111.3% | ||
| Q3 25 | -132.7% | 32.4% | ||
| Q2 25 | -124.9% | 26.9% | ||
| Q1 25 | -222.8% | 28.5% | ||
| Q4 24 | -105.1% | 98.9% | ||
| Q3 24 | -104.6% | 25.7% | ||
| Q2 24 | -317.9% | 38.2% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 4.5% | ||
| Q3 25 | 16.1% | 0.6% | ||
| Q2 25 | 12.4% | 1.6% | ||
| Q1 25 | 12.6% | 2.0% | ||
| Q4 24 | 5.7% | 13.7% | ||
| Q3 24 | 3.9% | 2.4% | ||
| Q2 24 | 1.4% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.50× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.20× | ||
| Q1 25 | — | 1.27× | ||
| Q4 24 | — | 5.47× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 2.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
SMBK
| Net Interest Income | $45.9M | 85% |
| Noninterest Income | $7.9M | 15% |
